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Abstract
Boron neutron capture therapy (BNCT) is a form of chemically targeted radiotherapy that
utilises the high neutron capture cross-section of boron-10 isotope to achieve a preferential
dose increase in the tumour. The BNCT dosimetry poses a special challenge as the
radiation dose absorbed by the irradiated tissues consists of several dose components with
different relative biological effectiveness. Dosimetry is important as the effect of the
radiation on the tissue is correlated with the radiation dose. Consistent and reliable
radiation dose delivery and dosimetry are thus basic requirements in order to ensure
patient safety, comparability of results between different BNCT centers and to enable
comparison with other treatment modalities. The established international
recommendations for radiotherapy dosimetry are not directly applicable to BNCT. The
existing dosimetry guidance for BNCT provides recommendations for the dosimetric
methods but also calls for investigating for complementary methods for comparison and
improved accuracy.
In this thesis the quality assurance and stability measurements of the neutron beam
monitors used in dose delivery are presented. The beam monitors were found not to be
effected by the presence of a phantom in the beam and that the effect of the reactor core
power distribution was less than 1%. The weekly stability test for the beam monitoring
system with activation detectors has been generally reproducible within the recommended
tolerance value of 2%.
An established toolkit for epithermal neutron beams for determination of the dose
components is presented and applied in an international dosimetric intercomparison. The
measured quantities (neutron flux, fast neutron and photon dose) determined by the groups
participating the intercomparison were generally in agreement within the stated
uncertainties. However, the measurement uncertainties were large, ranging from 3-30% (1
standard deviation (SD)), depending on the method and depth of measurement,
emphasising the importance of dosimetric intercomparisons if clinical data is to be
compared between different centers.
Measurements with the Exradin type 2M ionisation chamber have been repeated in the
epithermal neutron beam in the same measurement configuration over the course of 10
years. The presented results exclude severe sensitivity changes to thermal neutrons that
have been reported for this type of chamber.
The feasibility of microdosimetry and polymer gel dosimetry as complementary
methods for epithermal neutron beam dosimetry are studied. For microdosimetry the
comparison of results with ionisation chambers and computer simulation showed that the
photon dose measured with microdosimetry was systematically lower than with the two
other methods. The disagreement was within the uncertainties. For neutron dose the
simulation and microdosimetry results agreed within 10% while the ionisation chamber
technique gave 10-30% lower neutron dose rates than the two other methods. The
response of the BANG-3 gel was found to be linear for both photon and epithermal
neutron beam irradiation. The need for consistent procedures with gel dosimeters was
emphasised to ensure reliable results. The dose distribution normalised to dose maximum
measured by MAGIC polymer gel was found to agree well with the simulated result near
the dose maximum while the spatial difference between measured and simulated 30%
isodose line was more than 1 cm. In both the BANG-3 and MAGIC gel studies, the
interpretation of the results was complicated by the presence of high-LET radiation.
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5Aims of the study
The aim of this thesis was to examine the existing dosimetric practice and to establish the
possibilities of potential complementary dosimeter types for epithermal neutron beam
dosimetry.
The specific aims of the study were as follows:
1) To present the routine quality assurance procedure and stability measurements to ensure
the reliability of the beam monitoring system at the FiR 1 epithermal beam in Finland.
(Study I)
2) To present and apply a dosimetric toolkit for epithermal neutron beam characterisation
in BNCT. (Studies II and III)
3) To use TEPC based microdosimetry to measure the neutron and the photon dose at FiR
1 BNCT facility and to compare the results with doses measured using dual ionisation
chamber technique and calculated using DORT computer code. (Study IV)
4) To study the response and to evaluate the additional information that could be obtained
by using polymer gels in BNCT dosimetry. (Studies V and VI)
In addition, stability results with ionisation chamber measurements (Kosunen et al. 1999)
are presented spanning the years 1997-2007.
61 Introduction
The concept of boron neutron capture therapy (BNCT) was first introduced by Locher
(1936). BNCT is a form of chemically targeted radiotherapy. It utilises the high neutron
capture cross-section of boron-10 isotope at low (thermal) neutron energies to achieve a
preferential dose increase in the tumour volume. In BNCT boron is first selectively
accumulated into the tumour by a tumour-specific boron carrier. The tumour and its
surroundings are then irradiated with epithermal neutrons. Neutrons slow down
(thermalise) in tissue and undergo capture reaction with the boron, causing an increased
dose in the areas where the boron is concentrated.
The general aim of radiotherapy is to deliver sufficient radiation dose to the intended
target to provide a therapeutic effect while minimizing the complications on healthy
tissue. The limit of the therapeutic dose is dictated by the tolerance of the surrounding
healthy tissues. The challenge in this is that the difference between the therapeutic dose
and the tolerance of the healthy tissue is generally small. Also, there is typically a strong
dependence between the radiation dose and the effect – either therapeutic effect on tumour
or adverse effect on healthy tissue. The effects and success of radiotherapy are thus
ultimately dependent on the accuracy of the delivered radiation dose. This is reflected in
the 2.5-5% (1 SD) accuracy recommendations for the patient dose for external
radiotherapy (ICRU 26, IAEA 2000).
The accuracy of radiation dose imposes requirements on all parts of the radiation
treatment procedure. The uncertainty associated with each individual step in the treatment
procedure increases the overall uncertainty. The role of dosimetry in the treatment chain is
focused on two aspects: beam calibration and verification of the calculated dose. Beam
calibration is a procedure where the relationship between the beam monitors and the dose
components of the beam are determined under well-defined standard conditions (IAEA
2001, Voorbraak and Järvinen 2003). Dosimetry under non-standard conditions is
performed in order to verify the correctness of treatment planning system (TPS)
calculations.
To ensure the comparability and critical appraisal of the results from various pre-
clinical radiobiological experiments, as well as the clinical trials, carried out in various
epithermal neutron beams, it is of crucial importance that the basic characteristics of the
neutron beam (beam geometry, neutron and photon spectra, absorbed dose and fluence
distributions) are determined in a coherent and reproducible way. Consistent dosimetry is
also a requirement for a reliable comparison with conventional radiotherapy or other
treatment modalities. In addition, the safety of treatments requires that the beam dosimetry
is accurately related to the readings of appropriate beam monitors.
The above sets the requirement that the basic dosimetric methods must be traceable to
the international measurement system. The international recommendations or Codes of
Practice for radiotherapy dosimetry, currently available for conventional photon and
electron beam therapy, and for (fast) neutron therapy (IAEA 1997; 2000) are not
applicable to BNCT due to the complexity of the mixed neutron and photon fields. The
guidance on acceptable dosimetric procedures specific to BNCT has been provided by a
joint effort of eleven European institutional partners (Voorbraak and Järvinen 2003). Apart
7from the recommended dosimetric methods, the pursue for complementary dosimetry
methods is motivated by the need for comparable measurements and more accurate
methods for dosimetry in BNCT (Voorbraak and Järvinen 2003).
In the Finnish BNCT project the dosimetric efforts have been previously reported in
six Ph.D. theses. As a part of his thesis Kosunen (1999) evaluated the feasibility of the
dual ionisation chamber method in the BNCT dosimetry and studied the accuracy of the
calculated dose distribution in phantoms in epithermal neutron beam. Reasonable accuracy
in determining photon and neutron absorbed doses with the dual ionisation chamber
method was found. Intercomparisons and validation procedures were recommended for
BNCT TPS’s due to lack of standard dosimetric methods and large uncertainties in the
measured dose. Aschan (1999) investigated the use of thermoluminescent dosimeters
(TLD) to determine the photon and neutron dose components of the absorbed dose. In
BNCT beams she reported 16% and 20% (1 SD) accuracy in measuring neutron and
photon absorbed dose, respectively, enabling in vivo measurements. Beam
characterisation measurements using Si(Li) diode, dual ionisation chambers and TLDs
with comparison to calculated results were presented as part of the work by Kortesniemi
(2002). He concluded that the TLD and ionisation chamber methods are functional, but
that the accuracy should be improved and found the accuracy of Si(Li) detector suitable
for neutron fluence measurements. The estimation of boron concentration in blood during
treatment was the topic of Ryynänen (2002). She found several kinetic models to be
accurate for the determination of the boron concentration and recommended their parallel
use to enhance the estimation. The topic of the thesis by Seppälä (2002) was the
calculational model of FiR 1 epithermal neutron beam for treatment planning in BNCT.
The beam model was found to be accurate for use in the TPS and the computer simulation
results were used in the assessment and development of dosimetric methods and dose
planning procedure. Kotiluoto (2007) reviewed computational radiation transport methods
and summarised the results of a newly developed radiation transport code MultiTrans. For
BNCT the MultiTrans code was found to model the neutron dose and the reaction rates
accurately, but the photon dose disagreed with the results obtained with other methods.
The current work presents quality assurance and stability measurements of the neutron
beam monitors (Study I). An established toolkit for epithermal neutron beams for
determination of the dose components is presented (Study II) and applied in an
international dosimetric intercomparison (Study III). The feasibility of microdosimetry
and gel dosimetry as dosimetric as complementary methods for epithermal neutron beam
dosimetry is studied (Studies IV-VI). Also, stability results with ionisation chamber
measurements (Kosunen et al. 1999) are presented spanning the years 1997-2007.
8Table 1. The dose components in tissue in an epithermal neutron beam and their source reactions. Example methods for determining the dose
components and their reported uncertainties are listed. The relevance of each dose component for the treatment can be appreciated through
their contribution to the total biologically weighted dose in normal brain (healthy tissue) and target (tumour).
Dose
component
Dose
due to
(particle)
Dose
deposited
locally*
(yes/no)
Particle
due to
(reaction)
Reaction
due to
(particle)
Example
method of
measurement
Measured
quantity
Required
calculated
result for
method
Reported
uncertainties (1
SD) of dose
component
(range, %)¤
Main source
of
uncertainty
Dg Photon No 1H(n,g)2H† nth Mg(Ar) IC Dg 2.4-10
Response to
nth
33.5 6.4
Dn Proton Yes 1H(n,n’)p nfast TE(TE) IC Dg + Dn + DN
Neutron
spectrum, nth
15-30
Uncertainty
in Dg
4.2 0.8
DN Proton Yes
14N(n,p)14C nth Foils Reaction rate nth_calc 1.4-7.4
& 16.2 3.1
DB a, Li-ion Yes
10B(n,a)7Li‡ nth Foils Reaction rate nth_calc 1.4-7.4
& 46.1 89.8
* Within appr. 10 µm from reaction site
† Also photon component in the incident neutron-photon beam
‡ Also a neglible source of 2.2 MeV photons
§ Less accurate result can be obtained without calculated nth
& For thermal neutron fluence nth
¤ In phantom at reference point. Rogus et al. (1994), Raaijmakers et al. (1995), Liu et al. (1996), Kosunen et al. (1999),
  Munck af Rosenschöld et al. (2003) and Riley et al. (2003)
£ % of total dose at 2.5 cm depth, 11 cm diameter beam aperture, blood boron-10 concentration 12 ppm (IAEA 2001)
Biologically weighted
dose at FiR 1£
Normal
brain
(%)
Target
(%)
92 Epithermal neutron beam dosimetry
The epithermal neutron beam used in clinical BNCT irradiations generates four absorbed
dose components in the irradiated tissue:
(1) the photon dose Dg
(2) the fast neutron dose Dn
(3) the nitrogen dose DN
(4) the boron dose DB.
The photon dose is delivered by electrons created in photon interactions in the tissue. The
photon dose is due to both the photon component present in the incident beam and the
photons created in the neutron capture reaction by hydrogen 1H(n,g)2H in tissue. The fast
neutron dose is mainly delivered by recoil protons from neutron scatter in hydrogen
1H(n,n’)p by fast and epithermal neutrons. The nitrogen dose is due to neutron capture
reaction in nitrogen 14N(n,p)14C and is delivered by protons. The combined fast neutron
and nitrogen dose is also called the neutron dose. The boron dose is due to boron neutron
capture reaction 10B(n,a)7Li and the dose is deposited by alpha-particles and recoiling
lithium ions. The boron neutron reaction gives also a minor contribution to the photon
dose, although it can be ignored due to its low prevalence over the hydrogen capture
reaction.
The meaning of different dose components from the clinical perspective can be
appreciated through the information in Table 1. 90% of the total absorbed dose to the
target (tumour) is delivered by the boron dose component only. The therapeutic dose to
the tumour is limited by the undesired absorbed dose to the normal brain tissue. 54% of
the dose to normal brain is due to the combined photon, fast neutron and nitrogen dose and
the remaining 46% is due to the boron dose. It is evident that from the clinical perspective
it is desirable to minimize the dose from the photon, fast neutron and nitrogen dose
components while maximising the boron dose to the intended target.
It is necessary to determine separately each of the four dose components as they have
different absorbed dose distributions and relative biological effectiveness (Zamenhof et al.
1975). This poses a challenge for the dosimetry.
The dosimetric quantities of interest for determining the four dose components are the
photon absorbed dose, the fast neutron absorbed dose and the thermal neutron fluence
(Voorbraak and Järvinen 2003). All the dose components can be determined from these
quantities as the thermal neutron fluence gives rise to the nitrogen and boron absorbed
doses. The photon and fast neutron absorbed doses are generally measured using the dual
ionisation chamber technique based on ICRU Report 45 (1989) for clinical fast neutron
beam dosimetry, and the thermal neutron fluence is measured by using activation detectors
(Rogus et al. 1994, Raaijmakers et al. 1995, Kosunen et al. 1999, Munck af Rosenchöld et
al. 2003, Riley et al. 2003).
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2.1 Toolkit for epithermal neutron beam dosimetry
A complete and portable set of dosimetric hardware and methods for determining neutron
spectrum in air and dosimetric quantities of interest in phantom has evolved from the
experience of the Finnish BNCT project (Study II). Dual ionisation chamber method is
used to determine the photon and the combined fast neutron and nitrogen absorbed dose
(ICRU 45, Kosunen et al. 1999). A magnesium ionisation chamber with argon gas
(denoted as Mg(Ar)) is used for the photon dose measurements. The ionisation chamber is
assumed to be insensitive to neutrons in the epithermal neutron beam. Ionisation chamber
made from A-150 tissue-equivalent (TE) plastic and filled with tissue-equivalent gas
(denoted as TE(TE)) is used to determine the neutron dose. Both detectors are calibrated
in a 60Co beam. Their relative sensitivity to the photon radiation of the epithermal neutron
beam were determined through calibrations in water in 60Co beam and 6 MV photon beam
of a medical linear accelerator (Kosunen et al. 1999). In order to calculate the absorbed
dose from the signal of the TE(TE) ionisation chamber, the change in the chamber’s
response in the epithermal neutron beam relative to the calibration beam needs to be taken
into account. To calculate this correction factor, the neutron spectrum at the measurement
location must be known.
The neutron spectrum and thermal neutron fluence determination require both
measurements with activation detectors and calculated results from a treatment planning
program or general radiation transport code. The ratio of the measured and calculated
reaction rates are used to correct the calculated neutron fluence.
The thermal neutron sensitivity of the nominally neutron insensitive Mg(Ar) ionisation
chamber has been reported to increase over time (Raaijmakers et al. 1996, Munck af
Rosenschöld et al. 2003). At the Finnish FiR 1 BNCT facility, Mg(Ar) ionisation chamber
measurements have been performed in the same measurement geometry over the course of
10 years. Results of these measurements are reported in this study.
2.2 Dosimetric intercomparison
BNCT is still an experimental form of radiotherapy and while a recommendation
(Voorbraak and Järvinen 2003) exists, there is no standardised method for the epithermal
neutron beam dosimetry. The aim of dosimetric intercomparisons in general is to establish
the accuracy and precision of dosimetry and to assess the consistency between centers
(Nisbet et al. 1998). By using a standard measurement technique and measuring system,
differences in the way that different centers carry out their dosimetry can be assessed
(Nisbet et al. 1998). Dosimetry intercomparisons are recognised to be effective in
revealing the presence of errors (WHO 1988). The aim of the dosimetric intercomparison
for BNCT (Study III) was to identify differences in determining the different dose
components between the participating groups. If the differences in the measured dose
quantities can be quantified, it would enable meaningful comparison of the experimental
and clinical results between different BNCT groups.
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In Study III, dosimetry comparisons was reported for three clinical centers in Europe,
located at the Nuclear Research Institute (NRI) Rez (Czech Republic), VTT Espoo
(Finland), and Studsvik Nyköping (Sweden) as well as for the center at MIT Cambridge
(USA). The work describes the first step of the investigation, which are the results of
dosimetry measurements between the various clinical centers that were performed in the
four different epithermal neutron beams. The second step is to provide conversion factors
to enable evaluation of total weighted dose between the participating centers (Riley et al.
in print).
Measurements were made both in air and in phantom. Epithermal neutron flux as well
as photon and fast neutron kerma rates were measured in air and the thermal neutron flux
together with the photon and fast neutron absorbed dose rates were measured in phantom.
A large, rectangular water-filled box of minimum linear dimensions 40´40´20 cm3 was
used as the common phantom with the beam impinging on the 40´40 cm2 face.
The principal method for determining the absorbed dose in tissue is to measure the
photon and fast neutron dose directly using dual ionisation chambers and activation foils
to separately account for the boron and thermal neutron dose (Rogus et al. 1994, Kosunen
et al. 1999, Munck af Rosenschöld et al. 2003, Riley et al. 2003). At Rez, the use of Si(Li)
diodes and TLDs is preferred (Marek et al. 2000). Activated foils were counted using
HPGe detectors at each host facility and then cross checked with subsequent
measurements back at the visitor’s home center. Applying the dosimetry techniques that
are standard clinical practice for each facility the absorbed dose was determined for the
three radiation components in the host’s most commonly used field under same conditions
2.3 Complementary dosimetry methods in epithermal
neutron beam
Dual ionisation chambers and activation detectors are often used and recommended
(Vorbraak and Järvinen 2003) to determine the basic dosimetric quantities in epithermal
neutron beams. Because of the unsatisfactory uncertainties and dependence on calculated
results, the current methods need validation and improvements (Rogus et al. 1994,
Raaijmakers et al. 1995, Kosunen et al. 1999, Munck af Rosenschöld et al. 2003, Riley et
al. 2003, Voorbraak and Järvinen 2003). There are several dosimeter types and methods
for BNCT dosimetry, including the examples shortly introduced in the following.
TLDs of several different types have been applied in BNCT (Perks et al. 1988,
Raaijmakers et al. 1995, Liu et al. 1996, Aschan et al. 1999, Gambarini et al. 2004,
Burgkhardt 2006). To determine both neutron and photon absorbed doses, two detectors
with different photon and neutron sensitivity are needed. The signals can be separated into
photon and neutron dose components as in dual ionisation chamber technique.
Fission counters, BF3 counters, boron lined proportional counters and 3He proportional
counters can be used for the detection of thermal neutrons (Tattam et al. 1998, Voorbraak
and Järvinen 2003, Riley et al. 2004). The method is based on measuring the pulses or
current produced by fission or neutron capture reactions of the respective isotope (235U,
10B or 3He).
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The use of Si(Li) semiconductor detectors is based on a lithium converter plate where
reaction 6Li(n,a)3H occurs. The semiconductor detector is used to measure the signal from
the alpha and triton particles and can be used to determine the relative thermal neutron
fluence distribution (Kortesniemi 2002, Marek and Viererbl 2004).
Measuring radiation dose with alanine detectors is based on electron paramagnetic
resonance (EPR) spectrum of the crystalline amino acid alanine. Radiation induces stable
radicals in alanine whose relative amount can be measured using EPR spectrum. The
alanine is sensitive to neutrons and in order to be used as photon dosimeter in BNCT, the
response due to neutrons needs to be taken into account (Marrale et al. 2008). EPR
dosimetry can also applied with lithium-containing formates and dithionates and offer a
possibility to measure the absorbed dose from photons and thermal neutrons in the
epithermal neutron beam (Lund et al. 2004).
2.3.1 Microdosimetry
Microdosimetric method using a tissue equivalent proportional counter (TEPC) can be
applied to measure the photon dose and the neutron dose (Wuu et al.1992, Kota et al.
2000, Burmeister et al. 2001). Also the boron dose can be measured as a special
application using a TEPC with 10B incorporated into the wall and gas of the detector (Wuu
et al. 1992). Unlike in the dual ionisation chamber method, the counter is operated in pulse
mode. The pulse height difference between the events related to the photon dose and the
neutron dose enables the separation of these dose components. The calibration of the
detector relies either on an internal radiation source or in a distinct feature (proton edge) of
the measured pulse height spectrum. In the epithermal neutron beams used for BNCT
treatments the estimated uncertainties for the determination of photon and neutron
absorbed are 6-7% and 6% (1 SD), respectively (Wuu et al. 1992, Kota et al. 2000,
Burmeister et al. 2001). The uncertainty for the neutron dose compares favourably to the
15-30% (1SD) range of uncertainties reported for the dual ionisation chamber method
(Rogus et al. 1994, Raaijmakers et al. 1995, Kosunen et al. 1999, Munck af Rosenchöld et
al. 2003, Riley et al. 2003). Published comparisons have shown differences in absorbed
doses measured using different methods. In a recent study (Burmeister et al. 2003)
microdosimetric method was compared with results from ionisation chamber, TLD and
activation foil measurements and a computer simulation in two different epithermal
neutron beams. Differences were found especially in the boron dose (10-20% difference),
but also in the neutron and photon dose, when determined using the different techniques.
In Study IV TEPC based microdosimetry was applied to measure the neutron dose and the
photon dose in a large water phantom at the FiR 1 BNCT facility. The results were
compared with doses measured using dual ionisation chamber technique and with doses
calculated using DORT computer code.
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2.3.2 Gel dosimetry
Polymer and Fricke gel dosimeters have been introduced as a potential tool for the
dosimetry of BNCT (Farajollahi et al. 2000, Gambarini et al. 2000). Ionising radiation
induces changes in these dosimeters (polymerisation in polymer gel dosimeters and
oxidation of ferrous ions into ferric ions in Fricke gel dosimeters) that can be quantified
using for example magnetic resonance imaging (MRI) or optical scanning. The main
advantages are that the dosimeter is tissue equivalent in main elemental composition and
that the method enables experimental determination of three dimensional dose distribution
in various volumes.
In Study V, BANG-3 (MGS Research Inc.) gel vials from three production batches
were irradiated with 6 MV photons of a Varian Clinac 2100 C linear accelerator and in the
epithermal neutron beam of the Finnish BNCT facility at the FiR 1 nuclear reactor. The
gel is tissue equivalent in main elemental composition and density, and its R2 relaxation
rate is dependent on the absorbed dose. The R2 relaxation rate map of the irradiated gel
vials was measured with a 1.5 T MRI scanner using spin echo sequence. The absorbed
dose of neutron irradiation was calculated using DORT computer code, and the accuracy
of the calculational model was verified by measuring the photon dose with TLDs and
55Mn(n,?) activation reaction rate with activation detectors.
Polymer gel dosimeter known by the acronym MAGIC was tested for evaluation of its
use in BNCT dosimetry in Study VI. A large (diameter 10 cm, length 20 cm) cylindrical
gel phantom was irradiated in the epithermal neutron beam at the FiR 1 nuclear reactor.
The neutron irradiation was simulated with a Monte Carlo radiation transport code MCNP.
Gel samples from the same production batch were also irradiated with 6 MV photons from
a medical linear accelerator to compare dose response in the two different types of beams.
The irradiated gel phantoms were imaged using MRI to determine their R2 relaxation rate
maps. The measured and normalised dose distribution in the epithermal neutron beam was
compared to the dose distribution calculated by the computer simulation.
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3 Beam monitors and quality assurance
The beam calibration is a procedure where the relationship between the beam monitors
and the dose components of the beam are determined under well-defined standard
conditions (IAEA 2001, Voorbraak and Järvinen 2003). The task of the beam monitors is
to establish an unambiguous relation between significant free-beam parameters and the
radiation field generated in the target, a phantom or a patient. From clinical treatment
perspective, the beam monitors are used to measure the radiation dose given to the patient.
Thus the accuracy and precision of the given radiation dose is directly dependent on the
reliability of the beam monitors.
Requirements for a beam monitoring system at a neutron irradiation facility for BNCT
have been given in the Recommendations for the Dosimetry of Boron Neutron Capture
Therapy (Voorbraak and Järvinen, 2003). The quantities to be monitored are the
epithermal neutron fluence and fluence rate, the epithermal neutron fluence spatial
uniformity and the photon fluence and fluence rate. Double redundant monitoring for the
epithermal fluence rate is required. The impact of the presence of patient or phantom in
the beam should be minimal on the monitor reading. As the main tool of the periodic
quality control of a beam monitor system repeated measurements for the ratio of the beam
monitor count rate to the reaction rate of activation foils (primarily 55Mn(n,g)) in a quality
control phantom are suggested.
The beam monitoring system at FiR 1 consists of four 235U fission chambers placed at
different positions around the beam collimator. Two of the chambers (N1 and N4) monitor
only epithermal neutrons and two chambers (N2 and N3) monitor the whole neutron
energy range. Photon radiation is monitored by a single ionisation chamber. The beam
monitoring system described in detail by Tanner et al. (1999). The beam monitoring
system is used also in all dosimetric work to form a common reference between the
measurements.
3.1 Sensitivity and stability of beam monitors
As described in detail in Study I, the sensitivity and stability of the beam monitors at FiR
1 were studied with activation detector and ionisation chamber measurements.
Sensitivity of the beam monitors to a target in the beam was checked by remotely
placing the PMMA phantom with 20 cm diameter and 24 cm length into the beam aperture
with one end of the cylinder facing the beam. The reactor was running at the power level
used in the clinical irradiations.
The sensitivity of the beam monitors to the power distribution in the reactor core was
studied by significantly varying the height positions of the reactor control rods and
observing the ratio of the signals from TE(TE) and Mg(Ar) ionisation chambers inside a
large water phantom at 2 cm and 8 cm depths relative to the three different neutron and
one photon monitor channel count rates.
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The stability and reproducibility of the beam monitors are routinely checked before
each patient irradiation by gold and manganese activation foils irradiated at 2 cm depth
along the central axis in the cylindrical PMMA phantom. The reaction rates are scaled to
the reference monitor count rate and compared to the reference values. Also the ratios of
signal from beam monitors (N1/N2 and N3/N1) are compared to reference values.
Calibration of the beam monitors for different reactor power levels are needed since
several types of measurements are performed at lower power levels than those used in
patient irradiations. Due to saturation phenomenon in the pulse counting system of the
beam monitors, extrapolation to full power cannot be simply done by scaling the results by
the monitor count rate ratio. Through activation method it is possible to establish an
unambiguous relationship between the monitor count rate and neutron flux. The gold and
manganese reaction rates at 2 cm depth in the cylindrical PMMA phantom were measured
at 100, 50 and 10 kW and compared to the values obtained at full power (250 kW).
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4 Results
4.1 Toolkit for epithermal neutron beam dosimetry
Although a recommendation exists, there is no single internationally accepted standard
method for dosimetry in epithermal neutron beams. Study II presents a complete example
of the hardware and methods required to determine basic epithermal neutron beam
characteristics. This mobile toolkit has evolved from the experience of the Finnish BNCT
project and has been used in BNCT facilities worldwide.
4.2 Dosimetric intercomparison
International dosimetry exchange for BNCT in which four facilities participated (Study
III) is a part of the effort to enable comparison of clinical data between different BNCT
centers. The measured quantities (neutron flux, fast neutron and photon dose) determined
by the participating groups were generally in agreement within the stated uncertainties.
To provide quantitative comparison of the doses measured by the participants, scaling
factors were provided. The factor was calculated separately for each dose component by
scaling the depth dose data measured by MIT so that it matched (sum of the squared
residuals minimised) the values measured by the participating institute. The scaling factors
are given in Table 2. The scaling factors for the MIT dose components are unity. The
dosimetric team from MIT performed measurements at all the other three institutes
participating in the intercomparison, so MIT results were used as the reference out of
convenience. One specific feature in the results is the lack of scaling factor for fast neutron
dose for FiR 1. This is because the measurements at FiR 1 did not yield any fast neutron
dose. The standard method at FiR 1 with the dual ionisation chambers is to measure
absorbed total neutron dose to brain tissue. For the purposes of this study the fast neutron
dose was determined by subtracting the nitrogen dose from the measured total neutron
dose. The total neutron dose measured by us agreed within uncertainties with the results
from a SERA computer simulation and was consistent with previously reported results
measured in a similar setup (Kosunen et al. 1999).
 The measurement uncertainties (Table 3) were large, ranging from 3-30% (1 SD),
depending on the method and depth of measurement and the possibility of clinically
significant systematic differences in the absorbed dose specification by individual groups
exists. Normalising the dose components to the results obtained using a single method in
all beams could improve the precision. The results emphasise the importance of dosimetric
intercomparisons in BNCT if clinical data is to be compared between different centers.
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Table 2. Scaling factors needed to multiply the results of measurements for each dose
component to match the results measured by MIT. The MIT results are chosen as the
reference based on convenience and does not imply that the MIT results are more
accurate than the others.
MIT Studsvik VTT NRI
Thermal neutron 1.00 1.04 0.96 1.00
Photon 1.00 1.00 0.99 1.12
Fast neutron 1.00 0.70 - 1.01
Table 3. Measurement uncertainty estimated or the three dose components for the groups
participating in the dosimetric intercomparison.
MIT Studsvik VTT NRI
Thermal neutron flux 4.0-6.5 3.0-4.0 5.0 10
Photon 4.4 6.0 6.0 20
Fast neutron 30 25 21 5.0
Absorbed dose component Uncertainty (1 SD) %
4.3 Ionisation chamber response stability
At FiR 1, measurements with the Exradin type 2M ionisation chamber (ser. no. 183) have
been repeated in the same measurement configuration over the course of 10 years. The
measurements were performed in the cylindrical extension (Ø 20 cm, length 20 cm) of a
large cubic water phantom at 2.5 and 6.0 cm depths along the center-line of the beam and
the results were calculated according to the methodology presented by Kosunen et al.
(1999). The measurement parameters and results are collated in Tables 4 and 5.
Calibration factor for air kerma for the ionisation chamber have been determined by
STUK Radiation and Nuclear Safety Authority in a 60Co beam. The change in the
chamber’s sensitivity to the predominantly 2.2 MeV photons present in the phantom in the
epithermal neutron irradiation have been determined through calibrations in water in 60Co
beam and 6 MV photon beam of a medical linear accelerator. Beam monitoring system
has been used to scale the current measured with the ionisation chamber to the reference
monitor unit count rate.
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Table 4. Photon absorbed dose measurements at 2.5 cm depth in the cylindrical extension
of a water phantom between years 1997 and 2007. The calibration coefficients have been
determined for the IC (Exradin M2, ser. no. 183) by STUK Radiation and Nuclear Safety
Authority in a 60Co beam. Beam monitor unit rates were used to normalise the dose to
reference conditions.
Difference
Calib. coeff. Current MU MU Current Dose rate to 1997
Date (mGy/nC) (pA) (cts/s) (cts/s) (pA) (Gy/h) (%)
Dec 1997 36.93 51.91 35185 34852 51.42 6.80 -
Aug 2004 36.70 56.14 33895 32034 53.06 6.98 2.5
Sep 2005 36.70 55.58 33298 32034 53.47 7.03 3.3
Feb 2006 36.70 54.39 32884 32034 52.99 6.97 2.4
Dec 2007 36.77 59.01 35235 32034 53.65 7.07 3.9
Reference (250 kW) conditionsMeasurement conditions
Table 5. Photon absorbed dose measurements at 6.0 cm depth in the cylindrical extension
of a water phantom between years 1997 and 2007. The calibration coefficients have been
determined for the IC (Exradin M2, ser. no. 183) by STUK Radiation and Nuclear Safety
Authority in a 60Co beam. Beam monitor unit rates were used to normalise the dose to
reference conditions.
Difference
Calib. coeff. Current MU MU Current Dose rate to 1997
Date (mGy/nC) (pA) (cts/s) (cts/s) (pA) (Gy/h) (%)
Dec 1997 36.93 37.44 35064 34852 37.22 4.92 -
Aug 2004 36.70 39.73 33967 32034 37.47 4.93 0.1
Sep 2005 36.70 35.54 33175 32034 34.32 4.51 -8.4
Feb 2006 36.70 39.78 32874 32034 38.76 5.10 3.5
Dec 2007 36.77 42.71 35239 32034 38.83 5.11 3.9
Measurement conditions Reference (250 kW) conditions
4.4 Complementary dosimetry methods in epithermal
neutron beam
Microdosimetry is a suitable measurement method for comparisons with dual ionisation
chamber method because microdosimetry is reported to have lower uncertainty in neutron
dose measurement and because the method is fundamentally different in respect of
detector calibration and separation of photon and neutron dose components. Example of a
measured microdosimetric spectrum and its separation into photon and neutron dose
components by fitting a reference spectrum from a 60Co source is shown in Figure 1.
Comparison of the results obtained with ionisation chambers, microdosimetry and
computer simulation are reported in Study IV. The measured and calculated doses are
shown in Figure 2. For photon dose the results from the computer simulation and the
ionisation chamber measurements agree within the experimental uncertainties. The photon
dose measured with microdosimetry is systematically lower than with the two other
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methods. For neutron dose the simulation and microdosimetry results agree within 10%
while the ionisation chamber technique gives 10-30% lower neutron dose rates than the
other two methods.
Figure 1. Measured microdosimetric (lineal energy) spectrum (solid line) at 25 mm depth
in a water phantom in the epithermal neutron beam at FiR 1. Photon spectrum from a
60Co photon beam (dashed line) was used to extrapolate the spectrum below the lowest
measured value and to separate the spectrum into areas corresponding to photon and
neutron absorbed dose.
Figure 2. Depth dose profiles at the beam center-line measured with microdosimetry
(TEPC), dual ionisation chambers (IC) and calculated with DORT computer code. Error
bars (8%) are only indicated for the photon dose measurements with the TEPC.
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BANG-3 polymer gel dosimeter measurements (Study V) were performed in photon
and epithermal neutron beams. The gel response in photon beam was shown to be linear
up to the highest used dose of 3.5 Gy. The dose response as the function of absorbed dose
in photon irradiation is shown in Figure 3. It shows the results from three different gel
production batches and also the dependence of the response on the time between the
irradiation and readout of the gel. The dose response in the epithermal neutron beam was
also shown to be linear. The calculated depth dose distribution and a representative gel
measurement normalised to the calculated total dose is shown in Figure 4. The pyrex glass
gel containers were found not to be ideally suited for epithermal neutron beam
measurements due to the presence of thermal neutron capturing boron-10, causing
uncertainties in the simulated results. For both photon and epithermal neutron beam
irradiations the gel sensitivity was shown to differ between different gel batches and also
depend on the time between irradiation and MRI imaging highlighting the need for
consistency and planning in all the procedures when applying the gel dosimeters.
Figure 3. Measured relaxation rate of the BANG-3 gel vials from three different
production batches as the function of calculated dose in a 6 MV photon beam. The gel
vials from the first batch were imaged twice: 5 h and 8 days after irradiation. Lines from
the least squares fit to the measured data are also shown.
The MAGIC polymer gel dosimeters used in Study VI were prepared from a single gel
batch and irradiated and imaged at scheduled intervals. The gel response in photon
irradiation was found to be linear while a 3% difference in sensitivity between the two
applied dosimeters was observed as shown in Figure 5. In epithermal neutron irradiation a
boron-free quartz glass container was used. The measured dose distribution normalised to
the dose maximum shown in Figure 6 was found to agree well near to the dose maximum,
while the spatial difference between simulated and measured 30% isodose line was more
than 1 cm. The dose response of the gel in the epithermal neutron beam appeared to be
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higher near the dose maximum where also the contribution from the high-LET (linear
energy transfer) particles is highest (20% of the total dose).
Figure 4. The depth dose curve at the FiR1 epithermal neutron beam in a water phantom
calculated with DORT computer code and the measured response of the a BANG-3 gel
dosimeter normalised to the calculated total dose.
Figure 5. Response of two MAGIC polymer gel vials irradiated with 6 MV photons in a
water phantom. A line is fitted to the data using the least squares method. The equation
and the correlation coefficient are shown.
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Figure 6. Left-hand side shows the comparison of calculated (solid line) and measured
(dashed line) isodoses at 10% intervals along the center cross-section of the gel cylinder
in irradiated the epithermal neutron beam. Representative axial measurement results at
the positions indicated by the arrows are shown on the right-hand side
4.5 Beam monitors and quality assurance
Main results from the quality control measurements in Study I regarding the beam
monitors are threefold. (1) The beam monitor count rate was not affected by the presence
of phantom in the beam and the sensitivity change for the reactor core power distribution
is less than 1%. (2) The activation reaction rates normalised to the primary beam monitor
has generally been reproducible within ±2%. The standard deviations are 1.6% and 1.7%
for Mn and Au reaction rates respectively. (3) Non-linearity correction was determined to
take into account the saturation effect in the pulse counting electronics which occurs at
high pulse rates. This correction factor for the beam monitor units to allow comparison of
measurements performed at different reactor powers. The correction factor to scale the
results to the nominal 250 kW reactor power for the most commonly used monitor unit
channel (N1) was 1.11 for the three tested reactor power levels of 100, 50 and 10 kW.
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5 Discussion and conclusions
5.1 Epithermal neutron beam dosimetry
5.1.1 Dual ionisation chamber method
Dual ionisation chamber technique is recommended as the reference method to determine
the beam profile for photons in air and in phantom and to measure neutron and photon
absorbed dose for beam calibration (Voorbraak and Järvinen 2003). The drawback of the
dual ionisation chamber method are the uncertainties related to the dose determination and
having to rely on calculated parameters (neutron spectrum at the measurement point) for
the determination of the (fast) neutron dose. The estimated 6.3% (1 SD) uncertainty for the
measured absorbed photon dose arises mainly from the uncertainty in determining the
chamber’s response to thermal neutrons. The response of the non-hydrogenous Mg(Ar)
chamber to thermal neutrons has been reported to change with time. For the neutron
absorbed dose, the 21.5% (1 SD) estimated uncertainty in the measured dose arises mainly
from the uncertainty of the photon dose, which is subtracted from the total dose measured
by the TE(TE) chamber.
The photon sensitivity factors of the ionisation chambers are used to take into account
the difference in the chambers’ response to the photons in the epithermal neutron beam
relative to the photons of the beam the chambers were calibrated in. These factors have
been assumed to be unity (Rogus et al. 1994, Raiijmakers et al. 1995) or have been
estimated from measurements in high-energy photon beams from clinical linear
accelerators (Raaijmakers et al. 1996, Kosunen et al. 1999). As elaborated by Munck af
Rosenschöld et al. (2002), the response of the ionisation chamber depends on the energy
and angle distribution of the photon fluence, and these can be different in epithermal
neutron beam than in either the photon beam of a clinical linear accelerator or 60Co photon
beam used in the calibration. Furthermore, placing the ionisation chamber into the
phantom causes a perturbation in the electron fluence. In the epithermal neutron beam
introduction of the ionisation chambers changes the photon production rate due to
difference hydrogen density between the phantom material and the detector. Correction
factors taking into account the above-mentioned factors have been calculated with Monte
Carlo simulations at Studsvik BNCT facility in Sweden (Munck af Rosenschöld et al.
2002). The correction factor was found to vary with depth and to differ from the photon
sensitivity factors derived from measurements in high-energy photon beams from clinical
linear accelerators. As the beam characteristics and phantom geometries differ between
BNCT facilities, the correction factors should be determined for each individual BNCT
beam. The results indicate that, in order to reduce the measurement uncertainty, the
experimentally determined photon sensitivity factor should be replaced with a
measurement-depth dependent correction factor taking into account the perturbation
effects caused by the detector in the phantom.
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Raaijmakers et al. (1996) studied the thermal neutron sensitivities of ionisation
chambers and TLDs used in the dosimetry of BNCT. They found out that the three tested
nominally neutron insensitive Mg(Ar) chambers (Exradin type 2M) displayed some
sensitivity to thermal neutrons (0.139-0.367´10-12 Gy cm2) and that during the course of
one year, the sensitivity of one the chambers increased by 70%. The cause of the thermal
neutron sensitivity and its increase was suggested to be due to chemical corrosion or
contamination of the chamber wall. The increase in sensitivity for the same type of
chamber was also observed by Munck af Rosenschöld et al. (2003). Thermal neutron
sensitivity was found to be 4.103´10-12 nC cm2 (0.169´10-12 Gy cm2) and it changed by
a factor of two in one year. The chamber was filled with argon gas during storage, but the
drift continued so that approximately 25% of the response at 3 cm depth in phantom was
due to thermal neutrons.
In the measurements presented in this thesis the Mg(Ar) ionisation chamber has been
assumed to be insensitive to thermal neutrons. This assumption is supported by
calculations showing a negligible kerma rate for magnesium due to thermal neutrons
(Raaijmakers et al. 1995) and the good agreement of the measured and calculated photon
and neutron doses (Kosunen et al. 1999). The uncertainty for the photon dose due to the
thermal neutron sensitivity was estimated to be 6.0% (1 SD) (Kosunen et al. 1999).
The thermal neutron fluence rate at FiR 1 along the central axis of the cylindrical water
phantom is 2.3´109 and 1.0´109 cm-2s-1 at 2.5 and 6.0 cm depth, respectively (Seppälä
2002). Assuming the smallest thermal neutron sensitivity of the values reported above, the
dose due to thermal neutrons would be 1.15 and 0.50 Gy/h at 2.5 and 6.0 cm depth,
respectively. If the 3.9% increase in the photon dose between 1997 and 2007
measurements reported in this study were due to increase in the chamber thermal neutron
sensitivity, the required increase in the thermal neutron sensitivity would be 28% at 2.5
cm depth and 38% at 6.0 cm depth. The observed changes in the measured photon dose
during the span of ten years excludes severe thermal neutron sensitivity changes of 50-
100% per year, as reported by Raaijmakers at al (1996) and Munck af Rosenschöld et al.
(2003).
5.1.2 Complementary dosimetry methods
Compared to the dual ionisation chamber method, microdosimetry provides an
independent method to measure photon and neutron absorbed dose. The detector can be
calibrated with its own internal radiation source (americium-244, emits alpha particles) or
using a feature in the measured pulse height spectrum of the mixed photon and neutron
beam. The microdosimetric method does not require knowledge of the neutron spectrum
and both the photon and the neutron dose can be determined from a single measurement.
With the system used in Study IV, two measurements with different amplification settings
are still needed, as the pulse-heights in the spectrum span five orders of magnitude.
However, the commercially available proportional counter (model LET-½, Far West
Technology, CA, USA) made from tissue-equivalent plastic is too sensitive to be used in
epithermal neutron beams at the power levels used in patient irradiations. Also, the need to
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process the measured pulse height spectrum to obtain the absorbed photon and neutron
doses may be considered a drawback. Smaller, less sensitive proportional counters have
been applied in epithermal neutron beam dosimetry (Burmeister et al. 2001, Moro et al.
2006). TEPC made from brain tissue equivalent A-181 plastic has been applied to measure
absorbed radiation dose to brain tissue (Burmeister et al. 2002). Dual TEPC technique
introducing a second counter with walls loaded with boron has been applied to determine
boron dose in addition to photon and neutron absorbed doses (Wuu et al. 1992, Kota et al.
2000, Burmeister et al. 2001, De Nardo et al. 2004). Apart from TEPC’s, microdosimetric
measurements can be performed with semiconductor or gas electron multiplier (GEM)
detectors (Bradley et al. 2001, Farahmand et al. 2004)
Apart from determining the absorbed dose, the microdosimetric spectrum can also be
used to assess the biological effectiveness of the radiation (ICRU 36). That has been done
in epithermal neutron beams (Burmeister et al. 2001, Hsu et al. 2003, Endo et al. 2004).
The relative biological effectiveness (RBE) determined from microdosimetric spectrum
can be used in assessing the results from radiobiological experiments in BNCT, such as
the determination of RBE for crypt cell regeneration in mice in epithermal neutron beams
(Gueulette et al. 2005).
The published uncertainty estimates related to dose measurements in epithermal
neutron beams using TEPC microdosimetry are 6.1-6.7% for photon and 6.0-6.1 for
neutron dose component, presumably referring to an interval of 1 SD (Kota et al. 2000,
Burmeister et al. 2001). These uncertainty estimations do not take into account the
perturbation effects of the dosimeter in the phantom. As with ionisation chambers, the
difference in the hydrogen content between the detector and the phantom will cause a
change in the rate of photon production in the neutron capture reaction in hydrogen. The
effect on photon fluence estimated by Munck af Rosenschöld et al. (2002) for the dual
ionisation chambers (-4.7% and -6.3% (1 SD) for TE(TE) and Mg(Ar) chamber,
respectively, at 3 cm depth at the epithermal neutron beam in Studsvik, Sweden). The
effect can be expected to be of the same order of magnitude for the commercially
available TEPC detector as its physical size is comparable to that of the ionisation
chambers used in Munck af Rosenschöld’s study. However, unlike in the dual ionisation
chamber method, in microdosimetry increased uncertainty in the photon dose component
does not directly affect uncertainty in the neutron dose component. This is because in
microdosimetry the neutron dose is obtained by separating the microdosimetric spectrum
into photon and neutron dose components, and not by subtracting the photon dose from
the total dose. The perturbation effect can be expected to be less significant for a smaller
detector such as the miniaturised dual TEPC for BNCT dosimetry reported by Moro et al.
(2006). The miniature detector has two cylindrical TEPC’s with 0.53 mm3 active volumes
built within the end of a 2.7 mm by 200 mm sleeve. It has been verified to accurately
measure photon dose in a 60Co beam up to 20 Gy/h dose rates (Moro et al. 2006). The 2.7
mm outer diameter of that detector can be compared to the 5 mm diameter of the miniature
TEPC reported by Burmeister et al. (2001), to the 19 mm diameter of the commercially
available TEPC detector (Far West Technology, CA, USA) and to the 11.5 mm diameter
of the Mg(Ar) ionisation chamber (Exradin model M2).
26
The value of gel dosimeters is not in absolute dosimetry, but in its potential to
determine two- or three-dimensional radiation dose distributions. Gel dosimeters are
divided into Fricke and polymer gel dosimeter dosimeter groups. The response of the
Fricke gels are based on the ferrous sulphate Fricke solution in a gel matrix (Gore et al.
1984). When Fricke solution is irradiated, water decomposition occurs and various
reactions lead to the conversion of ferrous ions (Fe2+) to ferric ions (Fe3+). Changes in the
ion concentration affect the T1 relaxation rate of water protons. The observed change is
dose dependent and can be imaged using MRI or optical measurements. Main drawback of
the Fricke gel is that the diffusion of the ferrous and ferric ions deteriorates the dose
distribution and constrains the time between the irradiation and the measurement of the
dose response. Polymer gel dosimeters introduced by Maryanski et al. (1993) can be
imaged days or weeks after irradiation and do not suffer from the blurring of the dose
distribution over time. Various different Fricke and polymer gel dosimeters exist with
differences in composition and properties (McJury et al. 2000, Chu 2001).
Fricke gel dosimeters have been applied by one research group (Gambarini et al. 2000,
2002, 2004, 2007) in epithermal neutron beam to determine separately photon dose, fast
neutron dose, nitrogen dose and boron dose. This has been achieved by using four
different Fricke gel dosimeter compositions and by correcting for the relative sensitivity of
the gel to the particles inducing the different dose components. The estimated
uncertainties of the dose components determined with this method have not been reported
to the author’s knowledge, but the gel dosimetry results have been verified to agree with
TLD measurements and with doses calculated by Monte Carlo simulation (Gambarini et
al. 2004). The uncertainty for Fricke gel dosimetry for photon radiotherapy has been
estimated to be 5% (MacDougall et al. 2002). Applying Fricke gel dosimetry to BNCT
introduces additional uncertainties such as estimating the gel response to dose components
other than the photon dose.
The benefit of polymer gel dosimeters over Fricke gels in BNCT is that the dose
distribution is stable over days after irradiations and thus do not require prompt reading
after irradiation (Maryanski et al. 1993). Polymer gel dosimeters are commercially
available (MGS Research Inc., CT, USA) or can be prepared relatively easily from their
basic ingredients. Apart from Studies V and VI, the polymer gel dosimeters have been
studied in an epithermal neutron beam by Farajollahi et al. (2000). They added boron to
the polymer gel to determine the absorbed dose enhancement due to boron neutron capture
reaction and compared the enhancement to results calculated with computer simulation.
Polymer gel dosimetry has found applications in radiotherapy due to its capability to
2D measure dose distributions. Other desirable properties of the gel dosimeters include
high spatial resolution, tissue equivalence in terms of density and elemental composition
and freedom in choosing detector size and geometry. In gel dosimetry measurements the
dosimeter itself can act as the phantom. Gel dosimeters of different sizes and geometries
are relatively easy to prepare as the geometry is defined by the gel container. When using
gel dosimetry to determine doses in electron or photon radiotherapy, the gel response can
be determined for example by using a 60Co photon source or in the radiotherapy beam
itself by relating the results to calibrated ionisation chamber measurements. Determining
the gel dose response in radiation beams with contribution from high-LET particles is
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more challenging (Ramm et al. 2000, Jirasek and Duzenli 2002, Gustavsson et al. 2004,
Baker et al. 2008). The response has been found to depend on the LET of the particle. The
LET response studies have been performed in proton and carbon ion beams, where the
main contribution of the doses is due to high-LET particles. At the FiR 1 epithermal
neutron beam the contribution of high-LET particles to total dose is at most 20% at 2 cm
depth and decreases with depth, so that the dose due to high-LET radiation is 3% at 10 cm
depth. In both the BANG-3 and MAGIC gel studies, though the response to total dose
(BANG-3) appeared linear and the relative dose distribution measurement agreed with the
simulation (MAGIC), the interpretation of the results is still complicated by the presence
of high-LET radiation.
5.1.3 Uncertainty of the dose to the patient
Accurate measurements of the neutron fluence and photon and neutron dose components
in a phantom is desirable at least for the purposes of beam calibration, beam
characterisation and TPS verification. However, in BNCT treatment the absorbed dose to
the irradiated tissues depends also on the patient positioning and the local concentration of
boron. The uncertainty of the patient dose due to the uncertainties in dosimetry,
positioning and boron concentration estimation has been presented in the work by
Kortesniemi (2002). The results show that the combined uncertainty of the total absorbed
dose to normal brain tissue without boron is 7% (1 SD) at the reference point (depth of
maximum thermal neutron fluence). When the boron dose is included, the uncertainty is
18% (1 SD). If the uncertainty related to dosimetry is assumed to be zero, the combined
uncertainty for absorbed dose with boron dose included is still 15% and 14% (1 SD) in
normal brain tissue and in the target tissue, respectively.
The main source of the patient dose uncertainty in BNCT treatment is the estimation of
boron concentration in the irradiated tissue. The boron concentration in blood is measured
(Laakso et al. 2001) before and after irradiation. The boron concentration in blood during
the irradiation is estimated for each patient (Ryynänen et al. 2000, Kortesniemi et al.
2004). The boron concentration in the tissues of interest is estimated from tissue-to-blood
ratios (Coderre and Morris 1999). This last step is the main source of the uncertainty in
determining the physical absorbed radiation dose in the patient (Kortesniemi 2002). In
addition, the RBE-weighted radiation dose is obtained by applying weighting factors to
the different physical dose components according to radiation type and, in the case of
boron dose, tissue of interest (IAEA 2001).
In order to improve the estimation of boron concentration in tissues application of
position emission tomography (PET), prompt gamma spectroscopy (PGS), 10B MRI and
1H MRI spectroscopy have been suggested. PET study using a boron carrier labelled with
18F can provide data on the extraction of boron carrier to the tumour and other tissues
(Kabalka et al. 1997). PGS can provide information on the biodistribution of boron during
irradiation (Verbakel et al. 2003). Proton magnetic resonance spectroscopy (1H MRS) has
been studied with the aim of in vivo quantification of boron carrier (Zuo et al. 1999,
Timonen et al. 2005). Magnetic resonance imaging and spectoscopy of isotopes 10B and
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11B have the potential for real-time monitoring of boron concentration in the patient, but
requires special hardware and suffers from low sensitivity (Bendel et al. 2001, Wittig et al.
2008).
The most important issues for the future of BNCT are focused mostly on optimising
and improving the biological and chemical aspects the treatment. In a recent review Barth
et al. (2005) named four issues for which development is critical for BNCT: more
selective and effective boron delivery agents, methods to provide semiquantitative
estimates of tumour boron content, improvement of clinical implementation of BNCT and
randomised trials to demonstrate the clinical efficacy.
5.2  Quality control measurements
The EU Council Directive on Health Protection (97/43/EURATOM) applies also to
exposure of patient as part of their treatment. The directive requires that appropriate
quality assurance programmes including quality control measures are implemented. In the
recommendations for dosimetry of BNCT (Vorbraak and Järvinen 2003) presents a set of
quality control procedures related to the beam calibration and patient dosimetry to meet
with the requirement. The recommended tests are listed in Table 6. In addition to the
quality assurance procedures, the recommendations include requirements for beam
monitors. These include establishing the linearity of the beam monitor system relative to
the dosimetric quantities and limiting the impact of patient or phantom on the monitor
reading to less than 2%.
The constancy of the neutron energy spectrum in air serves also as a test of the
simultaneously used beam monitors. The measurement is justified by the possible slight
change of neutron spectrum with the change of fuel element positions within the reactor
core. Thus, if the reactor cycle is longer than one year, the recommended annual test
would be relevant only as a check for the different beam monitor channels.
Beam calibration is the procedure where the relationship of the dosimetric quantities of
the radiation beam to the beam monitor units is determined in a reference position under
standard conditions. The dosimetric quantities in the recommendations are photon and fast
neutron absorbed dose and thermal neutron fluence. The photon and fast neutron doses are
to be determined with dual ionisation chamber method and verified with supplementary
method such as TLDs, microdosimetry or semiconductor detector. The thermal neutron
fluence is recommended to be determined with a set of three activation detectors. The
recommended phantom is a water phantom with PMMA walls with minimum dimensions
of 40´40´20 cm3. The measurement point is defined at the thermal neutron fluence
maximum at the central axis of the beam.
Depth absorbed dose with ionisation chambers or neutron fluence with activation foils
or Si(Li) diode is to be determined annually.
The recommended annual beam monitor tests are repeatability and linearity measured
with activation detectors. A weekly stability test with activation foils is also
recommended.
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Table 6. Recommended (Voorbraak and Järvinen 2003) functional performance
characteristics to be tested, tolerance values and test frequencies, with respect to
radiation output of BNCT facilities.
Performance characteristics Tolerancevalue
Test
frequency Method
Constancy of neutron
energy spectrum
±10% Annually and
for each
reactor cycle
Measurement with 10 or more different activation
detectors. Deviation of reaction rates relative to a
reference reaction rate measurement.
Beam calibration Annually and
for each
reactor cycle
Thermal neutron fluence, fast neutron absorbed
dose, photon absorbed dose. In phantom.
Depth absorbed dose or
neutron fluence
±5%* Annually Dual ionisation chambers, activation foils or Si(Li)
diode.
Beam monitoring system
Repeatability 0.5%
Linearity 0.5%
Stability 2.0%
Uniformity of radiation field
Indication for central axis
for beam entry
2 mm Weekly or for
each patient
Check of laser beam.
* Reproducibility of dose and fluence per reference monitor reading.
Repeated measurements for the ratio of the
detector count reate to the saturation count rate of
activation foils
The recommended annual test for the uniformity of radiation field is not well defined. It is
explained in the recommendations only as “agreement of measurement and calculation for
all dose components tested one initially”. This test appears to come from the work of
Rassow et al. (2001), where it is described in more detail. Rassow et al. explain that beam
uniformity and depth absorbed dose characteristics of BNCT radiation field must be
measured only once initially. The quality assurance program is then to verify that the
(intermediate) neutron energy spectrum is stable over time, which ensures that the depth
absorbed dose characteristics does not change. Also, if the neutron energy is stable, any
change in beam uniformity can be considered irrelevant for the example beam in the
article of Rassow et al. The recommendation appears to call for annual calculation of dose
components under reference conditions taking into account any changes in neutron
spectrum and comparing the results to existing set of initial measurements. If beam
uniformity could change without affecting the neutron spectrum, additional measurements
for determining possible changes in the beam uniformity are needed. Rassow et al. lists
the parameters to be determined as the same that are measured for medical linear
accelerators, such as width of beam penumbra. It can be questioned whether the
parameters defined for medical linear accelerators are relevant for epithermal neutron
beams due to fundamental differences in these radiation sources.
The quality assurance procedures at FiR 1 BNCT facility documented as part of the
quality manual for BNCT treatments and are based on the recommendations (Voorbraak
and Järvinen 2003). The neutron energy spectrum is measured annually with an activation
detector set. The constancy of the spectrum is estimated by calculating ratios of two
different reactions and comparing those to reference values. The tolerance is set to ±2%.
Beam calibration is performed annually in reference points both in air and in phantom.
Neutron dose and photon dose are determined with the dual ionisation chamber technique.
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Additionally a pair of activation detectors is used in phantom to measure thermal and
epithermal neutron flux. The beam depth profile is tested by measuring photon absorbed
dose with Mg(Ar) ionisation chamber and thermal and epithermal neutron flux with a
activation detector pair. Beam radial profiles at 25 mm and 60 mm depth are measured
with Mg(Ar) ionisation chamber and Mn activation detector. Deviation of ±5% of the
photon absorbed dose or neutron fluence from the reference values are accepted. The
beam monitoring system is tested annually for linearity and repeatability with activation
detector measurements. The tolerance value for these measurements is 0.5%. In addition,
the stability of beam monitors are checked with activation detectors with weekly
measurements with tolenrance set to 2%. Laser beam indicators for the beam central axis
are checked weekly and deviations of up to 2 mm are accepted.
The beam quality assurance procedures defined in the quality manual of the FiR 1
BNCT facility are consistent with the recommended procedures (Voorbraak and Järvinen
2003). The beam uniformity, which is ambiguously defined in the recommendations, is
tested be measuring depth profile of photon absorbed dose with ionisation chamber and
thermal and epithermal neutron flux with a pair of activation detectors. In addition, radial
beam profiles at 25 mm and 60 mm depth are measured with Mg(Ar) ionisation chamber
and Mn activation detector.
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6 Summary
BNCT is still an experimental form of radiotherapy practiced in a few research centers
worldwide. Although recommendations and comparisons have been published, there are
still no standardised methods for epithermal neutron beam dosimetry and calibration.
Standardisation of dosimetry is a foundation which would enable robust and direct
comparison of clinical and other results between different research centres. In this thesis
(1) the existing dosimetric practices and quality assurance at FiR 1 were presented and
studied, (2) established dosimetric methods were compared in an international dosimetry
exchange program, (3) two relatively new methods of dosimetry in BNCT -
microdosimetry and polymer gel dosimetry – were evaluated at FiR 1.
Study I presents quality assurance test for the neutron beam monitors at FiR 1. Beam
monitors were found to be insensitive to presence of patient or phantom in the beam. The
sensitivity to changes in the reactor core power distribution was found to be less than 1%.
The deviation of the beam monitor checks have typically been of the order of 2% or less.
These results are within the recommended tolerance values (Voorbraak and Järvinen
2003). Some measurements are performed at lower reactor power levels than those used at
patient irradiations. Correction factor for the non-linearity of the primary beam monitor is
determined to relate low power measurements to the reference reactor power.
The dosimetric toolkit at FiR 1 for measuring photon dose, total neutron dose, neutron
spectrum and neutron flux locally and at other research centers is reviewed in Study II.
Measurements are based on dual ionisation chamber technique and activation detectors.
The analysis of the results requires calculated values for the neutron spectra at the
measurement locations and as such the method does not provide a fully independent
method for neutron flux and dose determination.
Study III is an international comparison of absorbed dose measurements for BNCT.
Neutron fluxes and absorbed dose are measured both in air and in a water filled phantom.
The comparison is performed by one team (MIT) visiting three clinical BNCT centers in
Europe and an European team from VTT/REZ visiting MIT. Each participant performs
measurement according to their appropriate to their local practices. In the different beams
the agreement is generally consistent with the estimated uncertainties. However,
systematic differences of up to 10% are observed between groups in determining the
biologically weighted dose to brain tissue in an example and the difference should be
considered clinically significant.
Doses at FiR 1 epithermal neutron beam are determined by microdosimetry, ionisation
chambers and computer simulation and compared in Study IV. The study includes the
first results of microdosimetry applied in FiR 1 beam. The differences in the absorbed
dose are within the limits of the stated uncertainties.
In Study V BANG-3 type polymer gel dosimeters are evaluated for BNCT dosimetry.
The response of the gel dosimeters to the total absorbed dose in the epithermal neutron
beam is linear. However, the magnitude of the response relative to photon irradiated
samples varies between different gel dosimeter batches. The linearity of the dose response
implicated that BANG-3 gel dosimeters are suitable for measuring relative 2D dose
distributions.
32
Study VI contains the evaluation of the relatively inexpensive and easy to prepare
polymer gel known by the acronym MAGIC in BNCT dosimetry. The dose response of
the gel was studied by irradiating gel samples in both the epithermal neutron beam and in
a pure photon beam. The gel phantoms were imaged using MRI and the normalised dose
distribution was compared to the dose distribution calculated by computer simulation. The
properties of the gel makes it suitable for the determination of 2D relative dose
distributions in large volumes and complex geometries.
Significant increase in the thermal neutron sensitivity as an aging phenomenon of the
Mg(Ar) type ionisation chambers has been reported by two authors. As the ionisation
chamber is assumed to be insensitive to neutron, increase in its sensitivity would cause
significant additional uncertainties in determined with the dual ionisation chamber
method. Photon dose measurements with the Mg(Ar) ionisation chamber have been
performed at FiR 1 BNCT facility. Observed changes in measured photon dose between
years 1997 and 2007 at FiR exclude severe sensitivity changes of 50-100% per year, as
reported by the two authors.
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